Company

Bio-Path Holdings, Inc.

Headquarters: Bellaire, TX, United States

Employees: 10

CEO: Mr. Peter H. Nielsen MBA

NASDAQ: BPTH +1.98%

Market Cap

$6.8 Million

USD as of Jan. 1, 2024

Market Cap History

Bio-Path Holdings, Inc. market capitalization over time

Evolution of Bio-Path Holdings, Inc. market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Bio-Path Holdings, Inc.

Detailed Description

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing Liposomal Bcl-2 for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; Liposomal STAT3 that is in preclinical stage for the treatment of pancreatic cancer, non-small cell lung cancer, and AML; and prexigebersen-A for various solid tumors. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.

Top 1-year algo backtest: +287.69%

$10,000 in March 2023 would now be $38,769 by following this algorithm daily at market close.

Boost your stocks returns with Disfold AI... Now!

Try Disfold AI for FREE

Stocks & Indices

Bio-Path Holdings, Inc. has the following listings and related stock indices.


Stock: NASDAQ: BPTH wb_incandescent

Stock: FSX: IBPB wb_incandescent

Details

Headquarters:

4710 Bellaire Boulevard

Suite 210

Bellaire, TX 77401

United States

Phone: 832 742 1357